

Effector Cell Institute, Inc
(Nagoya Stock Market, Centrex:4567)
4-7-7 Aobadai Meguro-Ku,
Tokyo 153-0042
Japan

February 18, 2008

**Announcement of publication in Clinical Cancer Research of eMIP/ECI301 study
demonstrating enhanced ‘abscopal effect’ effective for metastatic cancers**

ECI301 (eMIP), a variant form of human chemokine*, not only enhanced antitumor radiation efficacy but also prevented tumor growth distant to the irradiation site, a phenomenon called the “Abscopal effect”. These experimental results were published in the February issue of *Clinical Cancer Research*, a journal of the American Association for Cancer Research**.

ECI301 is a product of Effector Cell Institute Inc. and in this paper, ECI members and its collaborators at the University of Tokyo presented data that support a new concept for cancer therapy, namely ECI301 administration after radiation treatment. They, showed the remarkable effectiveness of the treatment in preclinical studies with demonstrable systemic effect. The data provides encouragement for its therapeutic application in the treatment of advance metastatic cancer.

Although it is generally believed that chemotherapy for infectious diseases (antibiotics) is quite effective, many physicians and researchers especially those concerned with immunocompromised hosts know that it is difficult to eradicate infectious agents without functional leukocytes. Likewise, to prevent remaining tumor growth after killing a majority or part of tumor cells by radiation, functional recruited leukocytes are required. Anti-tumor chemotherapy usually induces various side effects to patients that includes severe damage of leukocytes. The treatment proposed circumvents this problem and with it, no side effects have so far been found.

Tumor-free long-term survival without significant toxicity was demonstrated with this treatment, and complete eradication of tumor from about half of the treated animals was found. Furthermore, ECI301 consistently induced the abscopal effect of radiation (a reaction occurring outside the zone of actual radiation absorption), which was not only tumor type independent but also occurred across a spectrum of tumor types. Lymphocyte subsets were specified that are involved in inhibition of the tumor growth at the irradiated and non-irradiated sites.

ECI has established manufacturing protocols of ECI301 in a GMP facility and is waiting for the final reports of toxicity studies in primates from Huntigndon Life Science in UK (no toxicity has been found) and formulation reports from Toyobo Co. Ltd. in Japan, to be used for Investigational New Drug (IND) filing this coming autumn. Phase I/II clinical studies will be



performed in the United States.

[Explanation of Terms]

*Chemokine (chemotactic cytokine) is generated from various cells, recruit various leukocytes, induce their migration at lower concentrations and stimulate various functions of the cells at higher concentration. About 50 chemokines are known.

**Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1 α . Shiraishi, K. et. al. Clin. Cancer Res. 14, 1159-1166. 2008

※You can freely access the abstract of this article in <http://clincancerres.aacrjournals.org>

(Contacts for inquiries or additional information)

Effector Cell Institute, Inc

Administrative Department

Tel: +81-3-5452-0662(DID) Fax: +81-3-5452-0663

<http://www.effectorcell.co.jp>